Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro Corrigendum in /10.3892/mmr.2021.12267

Lu,Jian; Luo,Jun-Hang; Pang,Jian; Cao,Jia-Zheng; Wu,Rong‑Hai; Tong,Zhu-Ting; Chen,Wei; Xie,Dan

doi:10.3892/mmr.2012.1017

Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro

Corrigendum in: /10.3892/mmr.2021.12267

Authors:
- Jian Lu
- Jun-Hang Luo
- Jian Pang
- Jia-Zheng Cao
- Rong‑Hai Wu
- Zhu-Ting Tong
- Wei Chen
- Dan Xie
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, P.R. China, Department of Urology, The Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen 529030, P.R. China , State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou 510080, P.R. China
Published online on: August 3, 2012 https://doi.org/10.3892/mmr.2012.1017
Pages: 1133-1139

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clusterin (CLU) is a glycoprotein that is overexpressed in a number of malignant tumors and has been proven to correlate closely with the chemoresistance of several cancer cells to chemotherapeutic agents. However, the effect of CLU expression on the chemoresistance of bladder cancer to epirubicin remains unknown. In the present study, we aimed to elucidate the role of CLU in the chemoresistance of bladder cancer cells to epirubicin. Lentivirus-mediated RNA interference was applied to knock down CLU in EJ bladder cancer cells. The efficiency was examined by RT-PCR and western blot analysis. After stable CLU silencing, an EJ cell line was established and cells were treated with or without epirubicin. Cell viability, migration, invasiveness, clone formation and cell cycle progression were assessed by MTT assay, wound healing assay, Matrigel invasion assay, plate clone formation assay and flow cytometry, respectively. The results indicated that lentivirus-mediated RNA interference effectively silenced CLU at the RNA and protein levels. CLU knockdown increased the cytotoxicity of epirubicin to EJ bladder cancer cells. Combined treatment with lentivirus-mediated shRNA targeting CLU and epirubicin had maximum effects in bladder cancer cells on cell viability, migration, invasiveness and clone-forming ability. Furthermore, cell cycle analysis indicated that CLU knockdown reinforced the efficacy of epirubicin on G0/G1 cell cycle arrest. Taken together, our results suggest that CLU silencing enhances chemosensitivity of EJ bladder cancer cells to epirubicin. Lentivirus-mediated shRNA targeting CLU may be an alternative approach in the treatment of bladder cancer.

View Figures

View References

1	Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 25:219–278. 2001. View Article : Google Scholar
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3	Richie JP: Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am. 19:521–527. 1992.PubMed/NCBI
4	Kuroda M, Niijima T, Kotake T, Akaza H and Hinotsu S: Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer - The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. Eur Urol. 45:600–605. 2004.
5	Djeu JY and Wei S: Clusterin and chemoresistance. Adv Cancer Res. 105:77–92. 2009. View Article : Google Scholar : PubMed/NCBI
6	Luo JH, Xie D, Chen W, et al: Correlation of clusterin expression to prognosis of bladder carcinoma. Ai Zheng. 24:743–747. 2005.PubMed/NCBI
7	He LR, Liu MZ, Li BK, et al: Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 1000:2354–2360. 2009.PubMed/NCBI
8	Cheng CY, Cherng SH, Wu WJ, et al: Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 69:145–154. 2012. View Article : Google Scholar : PubMed/NCBI
9	Narita S, So A, Ettinger S, et al: GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res. 14:5769–5777. 2008. View Article : Google Scholar
10	Li M, Gu FL, Li WB, Song YS, Zhou AR and Guo YL: Introduction of wild-type p53 gene downregulates the expression of H-ras gene and suppresses the growth of bladder cancer cells. Urol Res. 23:311–314. 1995. View Article : Google Scholar : PubMed/NCBI
11	Trougakos IP, So A, Jansen B, Gleave ME and Gonos ES: Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834–1842. 2004. View Article : Google Scholar
12	Lin X, Yu Y, Zhao H, Zhang Y, Manela J and Tonetti DA: Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis. 27:1538–1546. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M and Corti A: Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene. 21:4328–4334. 2002. View Article : Google Scholar
14	Blaschuk O, Burdzy K and Fritz IB: Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem. 258:7714–7720. 1983.PubMed/NCBI
15	Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
16	Miyake H, Gleave M, Kamidono S and Hara I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology. 59:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
17	Xie D, Sham JS, Zeng WF, et al: Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J Gastroenterol. 11:3285–3289. 2005. View Article : Google Scholar : PubMed/NCBI
18	Shannan B, Seifert M, Leskov K, et al: Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res. 26:2707–2716. 2006.PubMed/NCBI
19	Kruger S, Mahnken A, Kausch I and Feller AC: Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology. 67:105–109. 2006. View Article : Google Scholar : PubMed/NCBI
20	Miyake H, Chi KN and Gleave ME: Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 6:1655–1663. 2000.PubMed/NCBI
21	July LV, Beraldi E, So A, et al: Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 3:223–232. 2004.PubMed/NCBI
22	So A, Sinnemann S, Huntsman D, Fazli L and Gleave M: Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 4:1837–1849. 2005. View Article : Google Scholar : PubMed/NCBI
23	Yom CK, Woo HY, Min SY, Kang SY and Kim HS: Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 29:3909–3912. 2009.PubMed/NCBI
24	Lamoureux F, Thomas C, Yin MJ, et al: Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 71:5838–5849. 2011. View Article : Google Scholar
25	Baylot V, Andrieu C, Katsogiannou M, et al: OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2:Oct 20–2011.(Epub ahead of print).
26	Nishitsuji H, Ikeda T, Miyoshi H, Ohashi T, Kannagi M and Masuda T: Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect. 6:76–85. 2004. View Article : Google Scholar : PubMed/NCBI
27	Rubinson DA, Dillon CP, Kwiatkowski AV, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 33:401–406. 2003. View Article : Google Scholar : PubMed/NCBI
28	Chen Y, Lin MC, Yao H, et al: Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 46:200–208. 2007. View Article : Google Scholar
29	Manilla P, Rebello T, Afable C, et al: Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 16:17–25. 2005. View Article : Google Scholar : PubMed/NCBI
30	Bank A, Dorazio R and Leboulch P: A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann NY Acad Sci. 1054:308–316. 2005. View Article : Google Scholar : PubMed/NCBI